Prediction of survival by using diffusion-weighted imaging/apparent diffusion coefficient (ADC) and [18F]FET PET-derived parameters in recurrent glioblastoma patients treated with regorafenib who underwent PET/MR
Latest Information Update: 06 Jan 2022
At a glance
- Drugs TLX101-CDx (Primary)
- Indications Glioblastoma
- Focus Diagnostic use
Most Recent Events
- 06 Jan 2022 New trial record
- 01 Jan 2022 Results published in the British Journal of Radiology